Lilly Puerto Rico plant sold to Colombia drugmaker

A surplus Eli Lilly plant in Puerto Rico has a new owner, which intends to invest more than $90 million in upgrades and hire 350 workers.

On Tuesday, Lilly ($LLY) confirmed an Associated Press report that the company sold the plant in Guayama to Bogota, Colombia-based Laboratorios Biogen SA, which is not to be confused with U.S.-based Biogen.

Biogen SA intends to invest $92 million updating the facility, where it will manufacture APIs. The company is receiving $2 million in incentives from the government for the project, Gov. Alejandro Garcia Padilla told the news service, and intends to hire 350 workers within the next 5 years.  

Lilly announced in 2014 that it would close the plant in Guayama by the end of 2015, but was offering jobs to its 100 employees at a plant in Carolina about 50 miles away. Lilly said at the time it would take a $170 million charge to cover the costs of shuttering the Guayama facility.

The Carolina plant had benefited from $240 million in investments as part of Lilly’s buildup in insulin products. In November 2013, the facility was tagged with receiving a $200 million investment to increase its insulin API capacity and then in the next year got another $40 million for some oral solid-dosage work.

Related Articles: 
Lilly will close Puerto Rico plant, affecting 100 workers 
Lilly to invest $700M in plant expansions

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.